Literature DB >> 16609758

Canadian physicians' choices for their own colon cancer screening.

Mamoon Raza1, Charles Noah Bernstein, Alexandra Ilnyckyj.   

Abstract

INTRODUCTION: Compliance with colorectal cancer (CRC) screening in Canada is low. The aim of the present survey was to determine whether Canadian physicians older than 50 years were pursuing colon cancer screening. Specifically, physicians were asked to identify their modality of choice and identify their barriers to screening.
METHODS: Surveys were mailed to members, older than 50 years, of the Canadian Association of Gastroenterology, the Society of Obstetricians and Gynaecologists of Canada, the Canadian Society of Internal Medicine, the Canadian Psychiatric Association and the Canadian Association of Radiologists.
RESULTS: Of 2,807 surveys, 46% were returned. Screening for CRC was reported by 53% of respondents. The Canadian Association of Radiologists members (61%) and the Canadian Association of Gastroenterology members (61%) were more likely to be screened than other specialties (P<0.01 and P<0.05, respectively). Members of the Society of Obstetricians and Gynaecologists of Canada (44%) were least likely to be screened (P<0.001). Men (P<0.001) and Ontario physicians (P<0.01) were more likely to be screened than women and Canadian physicians from other provinces, respectively. Colonoscopy (56%) was the most common screening modality used, followed by fecal occult blood testing (27%). Respondents who had not been screened cited a lack of personal time (47%) and insufficient data to warrant screening (14%). DISCUSSION: More than one-half of all respondents were screened for CRC. Colonoscopy is the most common screening modality used. Lack of time is the most common reason cited for not participating in CRC screening.

Entities:  

Mesh:

Year:  2006        PMID: 16609758      PMCID: PMC2659906          DOI: 10.1155/2006/969832

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  13 in total

1.  Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

2.  The effect of fecal occult-blood screening on the incidence of colorectal cancer.

Authors:  J S Mandel; T R Church; J H Bond; F Ederer; M S Geisser; S J Mongin; D C Snover; L M Schuman
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening.

Authors:  Desmond Leddin; Richard Hunt; Malcolm Champion; Alan Cockeram; Nigel Flook; Michael Gould; Young-In Kim; Jonathan Love; David Morgan; Susan Natsheh; Dan Sadowski
Journal:  Can J Gastroenterol       Date:  2004-02       Impact factor: 3.522

4.  Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.

Authors:  Charlene L Stokamer; Craig T Tenner; Jhuma Chaudhuri; Eva Vazquez; Edmund J Bini
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

5.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

Authors:  J S Mandel; T R Church; F Ederer; J H Bond
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

6.  A survey of women regarding factors affecting colorectal cancer screening compliance.

Authors:  David S Weinberg; Barbara J Turner; Hao Wang; Ronald E Myers; Suzanne Miller
Journal:  Prev Med       Date:  2004-06       Impact factor: 4.018

7.  Survey of colorectal cancer screening practices in a large Canadian urban centre.

Authors:  Lloyd A Mack; Heather Stuart; Walley J Temple
Journal:  Can J Surg       Date:  2004-06       Impact factor: 2.089

8.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

9.  A population-based estimate of the extent of colorectal cancer screening in Ontario.

Authors:  Linda Rabeneck; Lawrence F Paszat
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

10.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

View more
  6 in total

1.  Screening and the family physician.

Authors:  Nicholas Pimlott
Journal:  Can Fam Physician       Date:  2009-02       Impact factor: 3.275

2.  Impact of pharmaceutical industry versus university sponsorship on survey response: a randomized trial among Canadian hepatitis C care providers.

Authors:  Robert P Myers; Abdel Aziz M Shaheen; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2007-03       Impact factor: 3.522

3.  Family physicians' choices of and opinions on colorectal cancer screening modalities.

Authors:  Michael Zettler; Brent Mollon; Vitor da Silva; Brett Howe; Mark Speechley; Chris Vinden
Journal:  Can Fam Physician       Date:  2010-09       Impact factor: 3.275

4.  Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour.

Authors:  Ryan Zarychanski; Yue Chen; Charles N Bernstein; Paul C Hébert
Journal:  CMAJ       Date:  2007-09-11       Impact factor: 8.262

5.  Adherence to colorectal cancer screening guidelines in Canada.

Authors:  Maida J Sewitch; Caroline Fournier; Antonio Ciampi; Alina Dyachenko
Journal:  BMC Gastroenterol       Date:  2007-10-02       Impact factor: 3.067

6.  Exploring physician specialist response rates to web-based surveys.

Authors:  Ceara Tess Cunningham; Hude Quan; Brenda Hemmelgarn; Tom Noseworthy; Cynthia A Beck; Elijah Dixon; Susan Samuel; William A Ghali; Lindsay L Sykes; Nathalie Jetté
Journal:  BMC Med Res Methodol       Date:  2015-04-09       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.